uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Sciences, Infectious Diseases.
Show others and affiliations
2015 (English)In: Lancet. Infectious diseases (Print), ISSN 1473-3099, E-ISSN 1474-4457, Vol. 15, no 2, 225-234 p.Article, review/survey (Refereed) Published
Abstract [en]

In the face of diminishing therapeutic options for the treatment of infections caused by multidrug-resistant, Gram-negative bacteria, clinicians are increasingly using colistin and polymyxin B. These antibiotics became available clinically in the 1950s, when understanding of antimicrobial pharmacology and regulatory requirements for approval of drugs was substantially less than today. At the 1st International Conference on Polymyxins in Prato, Italy, 2013, participants discussed a set of key objectives that were developed to explore the factors affecting the safe and effective use of polymyxins, identify the gaps in knowledge, and set priorities for future research. Participants identified several factors that affect the optimum use of polymyxins, including: confusion caused by several different conventions used to describe doses of colistin; an absence of appropriate pharmacopoeial standards for polymyxins; outdated and diverse product information; and uncertainties about susceptibility testing and breakpoints. High-priority areas for research included: better definition of the effectiveness of polymyxin-based combination therapy compared with monotherapy via well designed, randomised controlled trials; examination of the relative merits of colistin versus polymyxin B for various types of infection; investigation of pharmacokinetics in special patient populations; and definition of the role of nebulised polymyxins alone or in combination with intravenous polymyxins for the treatment of pneumonia. The key areas identified provide a roadmap for action regarding the continued use of polymyxins, and are intended to help with the effective and safe use of these important, last-line antibiotics.

Place, publisher, year, edition, pages
2015. Vol. 15, no 2, 225-234 p.
National Category
Infectious Medicine
URN: urn:nbn:se:uu:diva-245314DOI: 10.1016/S1473-3099(14)70850-3ISI: 000348410200032PubMedID: 25459221OAI: oai:DiVA.org:uu-245314DiVA: diva2:791090
Available from: 2015-02-26 Created: 2015-02-26 Last updated: 2015-03-12Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Cars, Otto
By organisation
Infectious Diseases
In the same journal
Lancet. Infectious diseases (Print)
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 124 hits
ReferencesLink to record
Permanent link

Direct link